Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vadadustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 known ✓ | Q9GZT9 | 19/20 | 0.89 |
| ▸ | EGLN3 known ✓ | Q9H6Z9 | 8/20 | 0.89 |
| ▸ | FLT1 | P17948 | 7/20 | 0.89 |
| ▸ | VEGFA | P15692 | 6/20 | 0.89 |
| ▸ | TET3 | O43151 | 1/20 | 0.89 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.89 |
| ▸ | ASPH | Q12797 | 1/20 | 0.89 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.89 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.89 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.89 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.89 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.89 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vadadustat SCHEMBL29357486 | 0.94 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFATET3 | |
| Vadadustat SCHEMBL1920738 | 0.94 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFATET3 | |
| Vadadustat SCHEMBL29405970 | 0.94 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL14308517 | 0.85 | EGLN1 (0.83) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL1921294 | 0.85 | EGLN1 (0.77) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL21390798 | 0.85 | EGLN1 (0.82) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL30561704 | 0.84 | EGLN1 (0.75) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL1921240 | 0.84 | EGLN1 (0.75) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL1921387 | 0.84 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL30239178 | 0.84 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFATET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4095127-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3357911-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3026044-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-3357911-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3323807-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| EP-3026044-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20150119425-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT COMPANY, LLC (PR) | 2015-04-30 | — | — | US | disclosed |
| US-8722895-B2 | Prolyl hydroxylase inhibitors and method of use | AKEBIA THERAPEUTICS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130245076-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHOD OF USE | AKEBIA THERAPEUTICS INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8343952-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8323671-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2327696-A1 | Prolyl hydroxylase inhibitors and methods of use | Warner Chilcott Company, LLC (PR) | 2011-06-01 | — | — | EP | disclosed |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | disclosed |
| EP-2044005-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT CO LLC (PR) | 2010-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885FLT1 55/4885 |
| US-20130245076-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHOD OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885FLT1 55/4885 |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885FLT1 55/4885 |
| US-20150119425-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885FLT1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.